Linklaters advises on Neopharmed Gentili’s debut high yield offering, the largest refinancing of private credit debt with high yield bonds in Europe to date

Linklaters has advised the financing sources on the issuance by Neopharmed Gentili of two tranches of senior secured fixed and floating high yield notes, totalling €750m, as well as the entry into a new €130m revolving credit facility.

The offering represents the largest refinancing of private credit debt solely with syndicated high yield bonds in Europe to date.

Neopharmed Gentili (Ardian and NB Renaissance) is a leading primary care pharmaceutical company in Italy with a 50-year heritage.

The Linklaters high yield team was led by partner Giacomo Reali and included senior US associate Adriana Perez Cavazos, US associate Dami Banire and law clerk Filippo Turci. 

The Linklaters banking team was led by London partners Chris Medley and Rohan Saha with Milan partner Diego Esposito, Milan counsel Marco Carrieri and associate Giulia Oradei.

A cross-border tax team, coordinated by partner Roberto Egori and counsel Omer Harel, alongside counsel Fabio Balza, managing associate Eugenia Severino and Allan Paul Talde advised on Italian and US tax matters. The team was also supported by Milan partners Ugo Orsini and Lucio D’Amario, managing associates Marta Fusco and Giorgio Valoti, and associate Jacopo Cislaghi